Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a κ-Opioid Agonist in THC-Treated Mice

Daily treatment with cannabinoids results in tolerance to many, but not all, of their behavioral and physiologic effects. The present studies investigated the effects of 7-day exposure to 10 mg/kg daily of Δ(9)-tetrahydrocannabinol (THC) on the diuretic and antinociceptive effects of THC and the syn...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of pharmacology and experimental therapeutics Vol. 358; no. 2; pp. 334 - 341
Main Authors Chopda, Girish R, Parge, Viraj, Thakur, Ganesh A, Gatley, S John, Makriyannis, Alexandros, Paronis, Carol A
Format Journal Article
LanguageEnglish
Published United States The American Society for Pharmacology and Experimental Therapeutics 01.08.2016
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Daily treatment with cannabinoids results in tolerance to many, but not all, of their behavioral and physiologic effects. The present studies investigated the effects of 7-day exposure to 10 mg/kg daily of Δ(9)-tetrahydrocannabinol (THC) on the diuretic and antinociceptive effects of THC and the synthetic cannabinoid AM4054. Comparison studies determined diuretic responses to the κ-opioid agonist U50,488 and furosemide. After determination of control dose-response functions, mice received 10 mg/kg daily of THC for 7 days, and dose-response functions were re-determined 24 hours, 7 days, or 14 days later. THC and AM4054 had biphasic diuretic effects under control conditions with maximum effects of 30 and 35 ml/kg of urine, respectively. In contrast, antinociceptive effects of both drugs increased monotonically with dose to >90% of maximal possible effect. Treatment with THC produced 9- and 7-fold rightward shifts of the diuresis and antinociception dose-response curves for THC and, respectively, 7- and 3-fold rightward shifts in the AM4054 dose-response functions. U50,488 and furosemide increased urine output to >35 ml/kg under control conditions. The effects of U50,488 were attenuated after 7-day treatment with THC, whereas the effects of furosemide were unaltered. Diuretic effects of THC and AM4054 recovered to near-baseline levels within 14 days after stopping daily THC injections, whereas tolerance to the antinociceptive effects persisted longer than 14 days. The tolerance induced by 7-day treatment with THC was accompanied by a 55% decrease in the Bmax value for cannabinoid receptors (CB1). These data indicate that repeated exposure to THC produces similar rightward shifts in the ascending and descending limbs of cannabinoid diuresis dose-effect curves and to antinociceptive effects while resulting in a flattening of the U50,488 diuresis dose-effect function.
AbstractList Daily treatment with cannabinoids results in tolerance to many, but not all, of their behavioral and physiologic effects. The present studies investigated the effects of 7-day exposure to 10 mg/kg daily of Δ(9)-tetrahydrocannabinol (THC) on the diuretic and antinociceptive effects of THC and the synthetic cannabinoid AM4054. Comparison studies determined diuretic responses to the κ-opioid agonist U50,488 and furosemide. After determination of control dose-response functions, mice received 10 mg/kg daily of THC for 7 days, and dose-response functions were re-determined 24 hours, 7 days, or 14 days later. THC and AM4054 had biphasic diuretic effects under control conditions with maximum effects of 30 and 35 ml/kg of urine, respectively. In contrast, antinociceptive effects of both drugs increased monotonically with dose to >90% of maximal possible effect. Treatment with THC produced 9- and 7-fold rightward shifts of the diuresis and antinociception dose-response curves for THC and, respectively, 7- and 3-fold rightward shifts in the AM4054 dose-response functions. U50,488 and furosemide increased urine output to >35 ml/kg under control conditions. The effects of U50,488 were attenuated after 7-day treatment with THC, whereas the effects of furosemide were unaltered. Diuretic effects of THC and AM4054 recovered to near-baseline levels within 14 days after stopping daily THC injections, whereas tolerance to the antinociceptive effects persisted longer than 14 days. The tolerance induced by 7-day treatment with THC was accompanied by a 55% decrease in the Bmax value for cannabinoid receptors (CB1). These data indicate that repeated exposure to THC produces similar rightward shifts in the ascending and descending limbs of cannabinoid diuresis dose-effect curves and to antinociceptive effects while resulting in a flattening of the U50,488 diuresis dose-effect function.
Daily treatment with cannabinoids results in tolerance to many, but not all, of their behavioral and physiologic effects. The present studies investigated the effects of 7-day exposure to 10 mg/kg daily of Δ 9 -tetrahydrocannabinol (THC) on the diuretic and antinociceptive effects of THC and the synthetic cannabinoid AM4054. Comparison studies determined diuretic responses to the κ -opioid agonist U50,488 and furosemide. After determination of control dose-response functions, mice received 10 mg/kg daily of THC for 7 days, and dose-response functions were re-determined 24 hours, 7 days, or 14 days later. THC and AM4054 had biphasic diuretic effects under control conditions with maximum effects of 30 and 35 ml/kg of urine, respectively. In contrast, antinociceptive effects of both drugs increased monotonically with dose to >90% of maximal possible effect. Treatment with THC produced 9- and 7-fold rightward shifts of the diuresis and antinociception dose-response curves for THC and, respectively, 7- and 3-fold rightward shifts in the AM4054 dose-response functions. U50,488 and furosemide increased urine output to >35 ml/kg under control conditions. The effects of U50,488 were attenuated after 7-day treatment with THC, whereas the effects of furosemide were unaltered. Diuretic effects of THC and AM4054 recovered to near-baseline levels within 14 days after stopping daily THC injections, whereas tolerance to the antinociceptive effects persisted longer than 14 days. The tolerance induced by 7-day treatment with THC was accompanied by a 55% decrease in the B max value for cannabinoid receptors (CB1). These data indicate that repeated exposure to THC produces similar rightward shifts in the ascending and descending limbs of cannabinoid diuresis dose-effect curves and to antinociceptive effects while resulting in a flattening of the U50,488 diuresis dose-effect function.
Daily treatment with cannabinoids results in tolerance to many, but not all, of their behavioral and physiologic effects. The present studies investigated the effects of 7-day exposure to 10 mg/kg daily of Δ(9)-tetrahydrocannabinol (THC) on the diuretic and antinociceptive effects of THC and the synthetic cannabinoid AM4054. Comparison studies determined diuretic responses to the κ-opioid agonist U50,488 and furosemide. After determination of control dose-response functions, mice received 10 mg/kg daily of THC for 7 days, and dose-response functions were re-determined 24 hours, 7 days, or 14 days later. THC and AM4054 had biphasic diuretic effects under control conditions with maximum effects of 30 and 35 ml/kg of urine, respectively. In contrast, antinociceptive effects of both drugs increased monotonically with dose to >90% of maximal possible effect. Treatment with THC produced 9- and 7-fold rightward shifts of the diuresis and antinociception dose-response curves for THC and, respectively, 7- and 3-fold rightward shifts in the AM4054 dose-response functions. U50,488 and furosemide increased urine output to >35 ml/kg under control conditions. The effects of U50,488 were attenuated after 7-day treatment with THC, whereas the effects of furosemide were unaltered. Diuretic effects of THC and AM4054 recovered to near-baseline levels within 14 days after stopping daily THC injections, whereas tolerance to the antinociceptive effects persisted longer than 14 days. The tolerance induced by 7-day treatment with THC was accompanied by a 55% decrease in the Bmax value for cannabinoid receptors (CB1). These data indicate that repeated exposure to THC produces similar rightward shifts in the ascending and descending limbs of cannabinoid diuresis dose-effect curves and to antinociceptive effects while resulting in a flattening of the U50,488 diuresis dose-effect function.
Author Chopda, Girish R
Thakur, Ganesh A
Gatley, S John
Makriyannis, Alexandros
Paronis, Carol A
Parge, Viraj
Author_xml – sequence: 1
  givenname: Girish R
  surname: Chopda
  fullname: Chopda, Girish R
  email: cparonis@mclean.harvard.edu, girishchopda@yahoo.com
  organization: Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (G.R.C., V.P., G.A.T., S.J.G., A.M., C.A.P.); Dicerna Pharmaceuticals, Cambridge, Massachusetts (G.R.C.); Momenta Pharmaceuticals, Cambridge, Massachusetts (V.P.); Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P.) cparonis@mclean.harvard.edu girishchopda@yahoo.com
– sequence: 2
  givenname: Viraj
  surname: Parge
  fullname: Parge, Viraj
  organization: Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (G.R.C., V.P., G.A.T., S.J.G., A.M., C.A.P.); Dicerna Pharmaceuticals, Cambridge, Massachusetts (G.R.C.); Momenta Pharmaceuticals, Cambridge, Massachusetts (V.P.); Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P.)
– sequence: 3
  givenname: Ganesh A
  surname: Thakur
  fullname: Thakur, Ganesh A
  organization: Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (G.R.C., V.P., G.A.T., S.J.G., A.M., C.A.P.); Dicerna Pharmaceuticals, Cambridge, Massachusetts (G.R.C.); Momenta Pharmaceuticals, Cambridge, Massachusetts (V.P.); Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P.)
– sequence: 4
  givenname: S John
  surname: Gatley
  fullname: Gatley, S John
  organization: Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (G.R.C., V.P., G.A.T., S.J.G., A.M., C.A.P.); Dicerna Pharmaceuticals, Cambridge, Massachusetts (G.R.C.); Momenta Pharmaceuticals, Cambridge, Massachusetts (V.P.); Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P.)
– sequence: 5
  givenname: Alexandros
  surname: Makriyannis
  fullname: Makriyannis, Alexandros
  organization: Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (G.R.C., V.P., G.A.T., S.J.G., A.M., C.A.P.); Dicerna Pharmaceuticals, Cambridge, Massachusetts (G.R.C.); Momenta Pharmaceuticals, Cambridge, Massachusetts (V.P.); Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P.)
– sequence: 6
  givenname: Carol A
  surname: Paronis
  fullname: Paronis, Carol A
  email: cparonis@mclean.harvard.edu, girishchopda@yahoo.com
  organization: Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (G.R.C., V.P., G.A.T., S.J.G., A.M., C.A.P.); Dicerna Pharmaceuticals, Cambridge, Massachusetts (G.R.C.); Momenta Pharmaceuticals, Cambridge, Massachusetts (V.P.); Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P.) cparonis@mclean.harvard.edu girishchopda@yahoo.com
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27231154$$D View this record in MEDLINE/PubMed
BookMark eNpVkMtKBDEQRYMoOj7W7iRLN615d2cjSPsYQXEzrptMUtFIT9J2MoK_5kf4TY44iq7qQt06l1u7aDOmCAgdUnJCKROnzwOUlVInjDPK2QaaUMloRSjhm2hCCGMVl0ruoN2cnwmhQii-jXZYzTilUkzQMEs9jCZawCXh8gT4IixHKMHiS-_BloyTx62J0cxDTMFlbKLD7Zhyrv7dGvzxXt0PYeXB548phlxwiHg2bavZCKaAw3fBwj7a8qbPcLCee-jh6nLWTqvb--ub9vy2GphSpbKcKKZlTYXzoua00U5pq7llvgEiCeWNE1pRCzWXzNeNk_WqtVdMSD8Xju-hs2_usJwvwFmIZTR9N4xhYca3LpnQ_d_E8NQ9ptdOaKmJZivA8Rowppcl5NItQrbQ9yZCWuaONkQ0Uur6y3r0N-s35OfN_BMAEYGw
ContentType Journal Article
Copyright Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics 2016
Copyright_xml – notice: Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.
– notice: Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics 2016
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1124/jpet.116.232132
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Tolerance to Cannabinoid Diuresis
EISSN 1521-0103
EndPage 341
ExternalDocumentID 27231154
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIDA NIH HHS
  grantid: R21 DA035411
GroupedDBID ---
-~X
.55
.GJ
0R~
18M
2WC
3O-
4.4
53G
5GY
5RE
5VS
8WZ
A6W
AAJMC
AAYOK
ABCQX
ABIVO
ABJNI
ABOCM
ABSQV
ACGFO
ACGFS
ACNCT
ADBBV
ADCOW
ADIYS
AENEX
AERNN
AFFNX
AFHIN
AFOSN
AGFXO
AI.
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
F5P
F9R
GX1
H13
HZ~
INIJC
KQ8
L7B
LSO
MJL
MVM
NPM
O9-
OHT
OK1
P2P
R.V
R0Z
RHF
RHI
RPT
TR2
UQL
VH1
W2D
W8F
WH7
WOQ
X7M
YBU
YHG
YQT
ZGI
ZXP
7X8
5PM
ID FETCH-LOGICAL-p266t-c306295714df473189d69c93c2f8e050138d4961ce7352f78d57010f6245fb4d3
ISSN 0022-3565
IngestDate Tue Sep 17 20:45:01 EDT 2024
Sat Oct 26 01:26:18 EDT 2024
Sat Sep 28 08:49:01 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p266t-c306295714df473189d69c93c2f8e050138d4961ce7352f78d57010f6245fb4d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 27231154
PQID 1804855972
PQPubID 23479
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4959092
proquest_miscellaneous_1804855972
pubmed_primary_27231154
PublicationCentury 2000
PublicationDate 2016-08-00
20160801
PublicationDateYYYYMMDD 2016-08-01
PublicationDate_xml – month: 08
  year: 2016
  text: 2016-08-00
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Bethesda, MD
PublicationTitle The Journal of pharmacology and experimental therapeutics
PublicationTitleAlternate J Pharmacol Exp Ther
PublicationYear 2016
Publisher The American Society for Pharmacology and Experimental Therapeutics
Publisher_xml – name: The American Society for Pharmacology and Experimental Therapeutics
References 21246187 - Psychopharmacology (Berl). 2011 Jun;215(4):665-75
20354680 - Psychopharmacology (Berl). 2010 Jun;210(2):275-84
12943018 - J Abnorm Psychol. 2003 Aug;112(3):393-402
1992016 - J Neurosci. 1991 Feb;11(2):563-83
1666911 - Pharmacol Biochem Behav. 1991 Nov;40(3):471-8
2991502 - J Pharmacol Exp Ther. 1985 Aug;234(2):463-9
9389377 - Eur J Pharmacol. 1997 Oct 15;337(1):27-34
20664173 - J Clin Invest. 2010 Aug;120(8):2953-66
24099963 - Eur J Pharmacol. 2013 Dec 5;721(1-3):64-9
7996450 - J Pharmacol Exp Ther. 1994 Dec;271(3):1383-90
13621144 - J Ment Sci. 1958 Oct;104(437):972-99
8930163 - J Pharmacol Exp Ther. 1996 Nov;279(2):608-16
11826143 - J Neurosci. 2002 Feb 1;22(3):1146-54
16292318 - Neuropsychopharmacology. 2006 Sep;31(9):1957-66
26361728 - Pharmacol Res. 2015 Dec;102:22-32
16760363 - Mol Pharmacol. 2006 Sep;70(3):986-96
9918548 - J Pharmacol Exp Ther. 1999 Feb;288(2):478-83
8138952 - J Pharmacol Exp Ther. 1994 Mar;268(3):1381-7
23536317 - J Pharmacol Exp Ther. 2013 Jun;345(3):354-62
10087079 - J Neurosci. 1999 Apr 1;19(7):2658-64
22264443 - Biol Psychiatry. 2012 Apr 15;71(8):714-24
12235230 - J Pharmacol Exp Ther. 2002 Oct;303(1):36-44
10582605 - J Neurochem. 1999 Dec;73(6):2447-59
19284549 - Mol Pain. 2009 Mar 10;5:11
9422389 - J Neurochem. 1998 Jan;70(1):417-23
10940538 - Drug Alcohol Depend. 2000 Aug 1;60(2):113-9
17953671 - J Neurochem. 2007 Dec;103(6):2629-39
22718500 - J Pharmacol Exp Ther. 2012 Sep;342(3):843-9
23075707 - Behav Pharmacol. 2012 Dec;23(8):802-5
17967938 - J Pharmacol Exp Ther. 2008 Feb;324(2):664-73
23019138 - J Pharmacol Exp Ther. 2013 Jan;344(1):8-14
849066 - Arch Int Pharmacodyn Ther. 1977 Jan;225(1):77-87
11067978 - J Neurophysiol. 2000 Nov;84(5):2356-64
3039112 - J Pharmacol Exp Ther. 1987 Jul;242(1):33-9
16682964 - Br J Pharmacol. 2006 Jun;148(4):387-95
20344358 - Lancet. 1947 Aug 9;2(6467):223
16968947 - Pharmacol Rev. 2006 Sep;58(3):389-462
23197773 - J Pharmacol Exp Ther. 2013 Feb;344(2):319-28
16449088 - Am J Addict. 2006 Jan-Feb;15(1):8-14
References_xml
SSID ssj0014463
Score 2.2949898
Snippet Daily treatment with cannabinoids results in tolerance to many, but not all, of their behavioral and physiologic effects. The present studies investigated the...
SourceID pubmedcentral
proquest
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 334
SubjectTerms Adamantane - analogs & derivatives
Adamantane - pharmacology
Animals
Behavioral Pharmacology
Cannabinoids - pharmacology
Cannabinol - analogs & derivatives
Cannabinol - pharmacology
Cerebellum - drug effects
Cerebellum - metabolism
Cerebellum - physiology
Diuretics - pharmacology
Dose-Response Relationship, Drug
Dronabinol - pharmacology
Drug Tolerance
Male
Mice
Nociception - drug effects
Receptors, Opioid, kappa - agonists
Title Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a κ-Opioid Agonist in THC-Treated Mice
URI https://www.ncbi.nlm.nih.gov/pubmed/27231154
https://search.proquest.com/docview/1804855972
https://pubmed.ncbi.nlm.nih.gov/PMC4959092
Volume 358
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjtMwFLXKsGGDeFNeMhIzm06GxnEeXpZQWiENVCIjdVc5D9PwSKKSLOBj-BA-gm_i2nEStwwSsImiOA8p5-jec6-vrxF6BsGasIPUt3w75hYFB2GBbuaWR0TqOgkJhNrr8PyNt7ygr9fuejT6blQtNXV8lny7dF3J_6AK1wBXuUr2H5DtXwoX4BzwhSMgDMe_w7j8lO1Uzb9WkC_zRq1KnMyHMo2QFwWH-LfM07Yfcygdo7X3LJ8ch_PjFzPrbZXDfZPZ-1J21JXJkGgZWpFUlqBMz3WhXKdmh3VlStFWQxvstqvT3vYBxkqvXseH27JKlXxd5Gqr-37eaSUr1FURbr7jH4byFf6xURxbcLDR2yETu-C1zr6_G8qLdTbD9vpaOnBG2gITmd-YOqaJdtzA4CIxDK7TpkJ_dwSESkcAkQece2egG-02j2rQovqseEF8IlsO0cEj9nWK3dAVdJWAIZMWdLHuS4hkKO3odlHwvecHX5N9pvXzl4Uvh1W4hqyJbqDrGj08a8l1E42y4hY6WbVIfj3FkYHaKT7BKwPj26jqWYTrEgPCuGMg1gzEpcAmAzHwAh8wUD7L8c8fmn1Ysw_nBTbYhyX77qCLV_MoXFp6Dw-rAulXWwmEpIS5vk1TQX1wICz1WMLACoggm7pynjylzLOTzIdQQPhB6vqAvvAIdUVMU-cuOirKIruPMKdZGjMYdxKPxjZn8P-FzQSNWew5mT1GT7ufvAEbKSe-gIpl82VjB1PZA4n5ZIzutT99U7XNXDYdRGPk78HR3yD7r--PFPlW9WGnzGVTRh788Z0P0bWB44_QUb1rssegYev4iSLSL8o9n7M
link.rule.ids 230,315,783,787,888,27936,27937
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tolerance+to+the+Diuretic+Effects+of+Cannabinoids+and+Cross-Tolerance+to+a+%CE%BA-Opioid+Agonist+in+THC-Treated+Mice&rft.jtitle=The+Journal+of+pharmacology+and+experimental+therapeutics&rft.au=Chopda%2C+Girish+R&rft.au=Parge%2C+Viraj&rft.au=Thakur%2C+Ganesh+A&rft.au=Gatley%2C+S+John&rft.date=2016-08-01&rft.eissn=1521-0103&rft.volume=358&rft.issue=2&rft.spage=334&rft_id=info:doi/10.1124%2Fjpet.116.232132&rft_id=info%3Apmid%2F27231154&rft.externalDocID=27231154
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3565&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3565&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3565&client=summon